Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-39324 dose-escalation study versus Lucentis in exudative age-related macular degeneration
2009-015681-55Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Nov 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of linifanib and ranibizumab in exudative macular degeneration (6 arms), sponsored by Alcon Inc. Primary endpoint: Incidence of targeted adverse events in the study eye within 7 days. Started Nov 2009; status: completed.
02
Drugs
linifanibranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2009-015681-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015681-55.